ADAPTIVE BIOTECHNOLOGIES CORPORATION - COMMON STOC

7,4700

04-апреля-25 16:45:00

15 мин. задержка

Акции

+0,0600

+0,81%

Сегодняшний диапазон

6,6750 - 7,6200

ISIN

N/A

Источник

NASDAQ

Adaptive Biotechnologies Launches Assay Enhancements to Increase clonoSEQ® Sensitivity for Clinical MRD Detection in Diffuse Large B-Cell Lymphoma

11 мар 2025 08:00:00 Источник Nasdaq GlobeNewswire
Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2024 Financial Results

11 фев 2025 16:05:00 Источник Nasdaq GlobeNewswire
Adaptive Biotechnologies to Participate in Upcoming Investor Conferences

05 фев 2025 16:05:00 Источник Nasdaq GlobeNewswire
Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2024 Financial Results on February 11, 2025

22 янв 2025 16:05:00 Источник Nasdaq GlobeNewswire
Adaptive Biotechnologies and NeoGenomics Partner to Expand Access to Personalized Disease Monitoring for Blood Cancer Patients

14 янв 2025 07:30:00 Источник Nasdaq GlobeNewswire
Adaptive Biotechnologies Announces Clinical Lab Fee Schedule Rate of $2,007 for clonoSEQ® Test for Minimal Residual Disease Assessment is Effective as of January 1st, 2025

07 янв 2025 07:30:00 Источник Nasdaq GlobeNewswire
Adaptive Biotechnologies to Present at the 43rd Annual J.P. Morgan Healthcare Conference

02 янв 2025 16:05:00 Источник Nasdaq GlobeNewswire
Adaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in MRD Testing with clonoSEQ® and Its Impact on Blood Cancer Treatment Decisions

07 дек 2024 18:30:22 Источник Nasdaq GlobeNewswire
Adaptive Biotechnologies Announces Over 65 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 66th ASH Annual Meeting

03 дек 2024 07:30:25 Источник Nasdaq GlobeNewswire
Adaptive Biotechnologies Reports Third Quarter 2024 Financial Results

07 ноя 2024 16:05:01 Источник Nasdaq GlobeNewswire
Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Assessing Measurable Residual Disease in Mantle Cell Lymphoma

07 ноя 2024 07:30:55 Источник Nasdaq GlobeNewswire
Adaptive Biotechnologies to Report Third Quarter 2024 Financial Results on November 7, 2024

09 окт 2024 16:05:00 Источник Nasdaq GlobeNewswire
Adaptive Announces IVDR Certification for clonoSEQ® in European Union

29 авг 2024 07:30:15 Источник Nasdaq GlobeNewswire
Adaptive Biotechnologies to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

22 авг 2024 16:03:00 Источник Nasdaq GlobeNewswire
Adaptive Biotechnologies Reports Second Quarter 2024 Financial Results

01 авг 2024 16:05:00 Источник Nasdaq GlobeNewswire
Adaptive Biotechnologies to Report Second Quarter 2024 Financial Results on August 1, 2024

11 июл 2024 16:05:00 Источник Nasdaq GlobeNewswire
Adaptive Biotechnologies Announces Data Supporting the Clinical Benefits of MRD Assessment with clonoSEQ® To Be Presented at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress

31 май 2024 07:30:26 Источник Nasdaq GlobeNewswire
Adaptive Biotechnologies to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

29 май 2024 16:05:00 Источник Nasdaq GlobeNewswire
Adaptive Biotechnologies Reports First Quarter 2024 Financial Results

07 май 2024 16:05:46 Источник Nasdaq GlobeNewswire
Adaptive Biotechnologies to Report First Quarter 2024 Financial Results on May 7, 2024

17 апр 2024 16:05:00 Источник Nasdaq GlobeNewswire

<<
<
1
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.